Annual General Meeting of Kuros Biosciences approves majority of resolutions
Schlieren (Zurich), Switzerland, April 19, 2021 - Kuros Biosciences (SIX:KURN) today announced that its Annual General Meeting approved the majority of the resolutions proposed by the Board of Directors. Two proposed resolutions relating to the grant of options to the Board of Directors and to an amendment of the Articles for an increase in the conditional capital for employee share options did not reach the required majority. The Annual General Meeting approved the Annual Report, the Annual Financial Statements, and Consolidated Financial Statements for the year 2020 and took note of the Reports of the Auditors. Shareholders discharged the Board and the Executive Committee, voted in favor of the proposed appropriation of the Annual Results and approved the cash compensation for the members of the Board and the Executive Committee.
Kuros Biosciences Ltd.: Annual General Meeting of Kuros Biosciences approves majority of resolutions
Annual General Meeting of Kuros Biosciences approves majority of resolutions
Schlieren (Zurich), Switzerland, April 19, 2021 - Kuros Biosciences (SIX:KURN) today announced that its Annual General Meeting approved the majority of the resolutions proposed by the Board of Directors. Two proposed resolutions relating to the grant of options to the Board of Directors and to an amendment of the Articles for an increase in the conditional capital for employee share options did not reach the required majority.
The Annual General Meeting approved the Annual Report, the Annual Financial Statements, and Consolidated Financial Statements for the year 2020 and took note of the Reports of the Auditors. Shareholders discharged the Board and the Executive Committee, voted in favor of the proposed appropriation of the Annual Results and approved the cash compensation for the members of the Board an
Nicox Provides First Quarter 2021 Business Update and Financial Highlights apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
IS NOW APPROVED IN BRAZIL
SOPHIA ANTIPOLIS, France, and LAVAL, Quebec, April 16, 2021 – Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “Company”), Bausch + Lomb, its leading global eye health business, and Nicox (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, has received regulatory approval from the Brazilian Health Regulatory Agency (ANVISA – Agência Nacional de Vigilância Sanitária).
VYZULTA is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension in the United States and other territories that have the same indication.
1
“The approval of VYZULTA in Brazil marks its tenth regulatory approval. We will continue to focus our efforts on securing additional regulatory approvals for this important treatment option for people suffering from glaucoma to help address this
Identification of ten novel tumor-specific antigens immunogenic for T cells
Planegg/Martinsried and Montréal - 10 April 2021. Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, today presents the screening and identification of novel immunogenic tumor-specific antigens (TSAs) derived from non-coding regions of the human genome at the American Association for Cancer Research Virtual Annual Meeting (AACR) 2021. The poster can be found on Medigene s website: https://www.medigene.com/technologies/abstracts
Significant efforts are being dedicated worldwide to identifying novel TSAs as targets for cancer immunotherapy. In this respect, not only known proteins but also non-coding genetic regions of cells are studied as sources of peptides that can be presented by HLA molecules at the surface of tumor cells and be recognized by T cell receptors (TCRs). Such TSAs can provide new targets that all